MAIA Biotechnology (MAIA) Share-based Compensation (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Share-based Compensation for 6 consecutive years, with $16.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 39.56% year-over-year to $16.7 million in Q2 2026; TTM through Jun 2026 was $16.7 million, a 39.56% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, up 31.82% from the prior year.
• Share-based Compensation was $16.7 million for Q2 2026 at MAIA Biotechnology, up from $13.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $16.7 million in Q2 2026 and troughed at $488891.0 in Q4 2022.
• A 5-year average of $7.3 million and a median of $7.8 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 911.86% in 2023 and slumped 49.08% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $488891.0 in 2022, then surged by 178.58% to $1.4 million in 2023, then sank by 49.08% to $693443.0 in 2024, then climbed by 16.92% to $810796.0 in 2025, then surged by 1957.29% to $16.7 million in 2026.
• The last three Share-based Compensation figures came in at $16.7 million (Q2 2026), $13.1 million (Q1 2026), and $810796.0 (Q4 2025), per Business Quant data.